What Patients Need to Know About Immunotherapy in 2026
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
What Patients Need to Know About Immunotherapy in 2026
-
Narrated by:
-
By:
About this listen
In this episode of Bladder Cancer Matters, host Rick Bangs speaks with Dr. Josefa Briceno of AstraZeneca about why bladder cancer care may be at a true turning point. From exploring immunotherapy earlier in the disease journey — even around the time of surgery — to strengthening collaboration between urologists and medical oncologists, the conversation highlights how timing, teamwork, and informed shared decision-making are reshaping care.
Dr. Briceno explains what this shift means for patients, why education and self-advocacy are essential, and how partnerships between industry and advocacy organizations like BCAN help ensure innovation reflects real patient needs.
It's a hopeful, forward-looking discussion about where bladder cancer treatment is headed — and why patients should feel empowered to be active participants in their care.